Drawing for A&Z PHARMACEUTICAL INC.

USPTO serial 87365519

A&Z PHARMACEUTICAL INC.

Reviewed by CopyMark Law Group

Reg. 5358553Status 701Registered
Filing date
Status date
Registration date
Dec 19, 2017
Examiner
STINSON, JENNIFER ELLE
Law office
TMO LAW OFFICE 121

What this means

Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.

Status 701: Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary.

Need help with A&Z PHARMACEUTICAL INC.?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Dietary and nutritional supplements; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disordersACTIVEDec 1, 1996

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 1, 2024EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Oct 1, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 1, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 1, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 1, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 1, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED
Jun 30, 2023NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Jun 30, 20238.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Jun 30, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 9, 2023ES8RTEAS SECTION 8 RECEIVED
Dec 19, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 19, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 3, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 3, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 13, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 21, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Aug 11, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Aug 10, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 10, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 12, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 2, 2017DOCKASSIGNED TO EXAMINER
Mar 15, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 13, 2017NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance